DCR

ovarian cancer (OC) ovarian cancer (OC)

metastatic/advanced OC (mOC) - 1st line (L1) metastatic/advanced OC (mOC) - 1st line (L1)

mOC - L1 - all population metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - all population

mOC - L1 - PDL1 positive metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - PDL1 positive

metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)

versus pegylated liposomal doxorubicin
avelumab plus pegylated liposomal doxorubicin vs. pegylated liposomal doxorubicin 1 certainty unassessable+179%

metastatic/advanced OC (mOC) - maintenance (M) metastatic/advanced OC (mOC) - maintenance (M)